Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696009 | 0.83 | SIGMAR1 (0.36) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL26408395 | 0.82 | HRH3 (0.35) | HRH3MEN1KMT2AADRB2 | |
| SCHEMBL23945273 | 0.82 | SIGMAR1 (0.35) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL23696478 | 0.82 | HTR2C (0.35) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL23806682 | 0.77 | SIGMAR1 (0.35) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL24673860 | 0.75 | HRH3 (0.35) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL23945427 | 0.74 | SIGMAR1 (0.33) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL26408317 | 0.73 | SIGMAR1 (0.33) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL23572087 | 0.72 | HRH3 (0.36) | SIGMAR1DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL25122599 | 0.72 | ADRB1 (0.34) | SIGMAR1HRH3ADRB1LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | SIGMAR1 2516/4885DRD2 2705/4885HTR2A 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.